drugset
drugset / Trial / NCT03843125

A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)

NCT03843125 ↗

Phase 3 Terminated 1147 enrolled Eli Lilly and Company Incyte Corporation · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The reason for this long term study is to see how safe and effective the study drug known as baricitinib is in participants with systemic lupus erythematosus (SLE) who have completed the final treatment visit of study I4V-MC-JAHZ (NCT03616912) or study I4V-MC-JAIA (NCT03616964).

Timeline

Start
2019-09-09
Primary completion
2022-04-01
Completion
2022-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule 2 mg Oral
Subject Baricitinib Small molecule 4 mg Oral

Indications

systemic lupus erythematosus